US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Latest News about Perception Neuroscience

Recent news which mentions Perception Neuroscience

Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Tickers ATAI JNJ
Tags Benzinga Markets Drug Delivery Technologies
From Benzinga
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Tickers ATAI
Tags Penny Stocks Ketamine Therapy Treatment Resistant Depression
From Benzinga
Atai's Phase 2 Study For Treatment-Resistant Depression Completes Enrollment, Expects Results Soon
Tickers ATAI
Tags Benzinga ATAI Small Cap
From Benzinga
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
Tickers ATAI JNJ
Tags Florian Brand JNJ Terence Kelly
From Benzinga